Medical campaign to designate pain the “fifth vital sign”

The Medical campaign to designate pain the “fifth vital sign” recast pain from a symptom requiring clinical judgment into a routinely assessed measure with a place alongside blood pressure, heart rate, respiratory rate, and temperature. Emerging as OxyContin entered the market, the campaign joined legitimate concern about undertreated pain to new institutional standards and commercial promotion. Its central tension was that pain deserved more serious attention, while the tools used to standardize that attention could encourage opioid prescribing without establishing what adequate relief meant or how to measure its effects.

From undertreatment to a new standard

In 1996, the year OxyContin was introduced, doctors, hospitals, and accreditation boards were adopting the fifth-vital-sign approach. A broader change was already under way: patients were increasingly treated as health care consumers, and formal surveys, including those administered by Press Ganey, made their reported experiences consequential to providers. Doctors and hospitals competed for higher scores, while reimbursement pressures gave nurses and physicians an incentive to treat pain more liberally.

The institutional shift became more binding in 1999, when the Joint Commission on Accreditation of Healthcare Organizations approved mandatory standards for pain assessment and treatment. These standards answered a recognized problem. A 2000 article in The New York Times described an older nursing-home resident with severe osteoporosis and pulmonary disease who had been given only Tylenol, reflecting concern that outdated fears of addiction left patients in pain. But broad agreement that pain had been undertreated did not resolve the harder question of what adequate relief required.

Commercial alignment

Purdue Pharma saw the new standards as both a clinical opening and a business opportunity. Its budget plan described a chance to be regarded as pain experts and to help hospitals meet the Joint Commission requirements by supplying assessment and management materials. The planned materials included $300,000 in OxyContin-branded scroll pens, $225,000 in resource binders, and $290,000 in wall charts and clipboards bearing the phrase Pain: The Fifth Vital Sign. The campaign’s language could thus travel through hospital practice on branded objects as well as through formal policy.

That institutional strategy sat within an expansive promotional climate. After rules on pharmaceutical advertising were loosened, drug advertising rose from $360 million in 1995 to $1.3 billion in 1998, and companies increasingly used gifts to reach physicians. Purdue representatives targeted doctors identified through prescribing data and promoted OxyContin for noncancer pain, including back pain, osteoarthritis, injuries, and trauma. The company’s safety message relied on claims that addiction was rare: its representative, David Haddox, cited an addiction risk of less than 1 percent when the medication was taken as prescribed, while a 1996 training session characterized doctor-caused addiction as exquisitely rare.

Measuring pain, prescribing uncertainty

The campaign made pain easier to record and compare, but a numerical scale could give subjective experience an appearance of objectivity. No common definition settled what counted as adequate pain relief, and asking patients to rate pain could produce the same score for very different experiences: a person in labor and someone with a stubbed toe might each report a ten, depending on individual tolerance. Standardized assessment therefore did not itself establish that a treatment improved a patient’s outcome.

The book connects reliance on pain scales with increased opioid prescribing and abuse, while also recording clinicians’ later recognition that they had not understood the consequences. John Burton, head of emergency medicine at Carilion Clinic, recalled that physicians had been told to make pain a much higher priority; he said the result was more opioid prescribing without a sufficient grasp of what followed. He also acknowledged his own earlier belief that a patient could not become addicted to a fourteen-day supply of opioid pills, a belief he came to recognize as wrong.

Legacy and limits

The campaign’s legacy is not simply that pain was taken more seriously. It shows how a humane goal, converted into mandatory assessment and tied to patient ratings and reimbursement, could reshape ordinary clinical decisions. That system also offered Purdue Pharma a way to present its product as fitting the new standard of responsible care. The resulting expansion of opioid prescribing did not follow from the campaign alone, but the book identifies the measurement regime as one contributor to prescribing and abuse, while emphasizing how little agreement existed about the threshold between sufficient relief and excessive treatment.